Considering the relationship between the tumor mutation profile and immune checkpoint inhibitors, we examined the mRNA levels of several typical immune checkpoints (CD274, CTLA4, HAVCR2, LAG3, PDCD1, PDCD1LG2, TIGHT, and SIGLEC15) and found that the high-risk group had increased expression of some specific immune checkpoints, including CD274, HAVCR2, and SIGLEC15. This evidence concerns the gene SIGLEC15 and neoplasm.